4DMedical CT:VQ™ Lung Imaging in Australia

Could 4DMedical's CT:VQ™ Transform How Australia Diagnoses Lung Disease?

SaaS

4DMedical's TGA-approved CT:VQ™ technology eliminates need for contrast agents and nuclear medicine infrastructure.

First non-contrast CT ventilation-perfusion imaging solution approved in Australia
Eliminates need for injected contrast, radiotracers, and nuclear medicine infrastructure
Leverages existing CT scanner infrastructure already available across healthcare facilities
FDA-cleared technology deployed at leading US medical institutions since 2025

Australian respiratory diagnostics reached a significant milestone as 4DMedical Limited announced Therapeutic Goods Administration (TGA) approval for its CT:VQ™ technology, now registered on the Australian Register of Therapeutic Goods (ARTG). The approval enables commercial deployment across the country and marks a transformative moment for functional lung imaging in Australia's healthcare system. CT:VQ™ represents a breakthrough in non-contrast ventilation-perfusion imaging, delivering regional functional lung information directly from routine chest CT scans without requiring injected contrast agents, radiotracers, or dedicated nuclear medicine infrastructure. The software-based solution integrates seamlessly with existing CT imaging infrastructure already widely available throughout Australian healthcare facilities.

Andreas Fouras, Founder, Managing Director and CEO of 4DMedical, highlighted the significance of the approval for the domestic market. "TGA approval marks an important milestone for respiratory diagnostics in our home market," Fouras stated. "As the first and only non-contrast, CT-based ventilation-perfusion imaging solution, CT:VQ™ gives healthcare providers detailed, functional lung information using infrastructure already available throughout the healthcare system." Traditionally, ventilation-perfusion imaging has required dedicated nuclear medicine equipment, specialized radiotracers, and complex operational workflows that limit availability to facilities with onsite nuclear medicine services. CT:VQ™ provides a scalable alternative that transforms standard CT scans into comprehensive functional lung assessments, potentially broadening access to diagnostic capabilities across metropolitan, regional, and rural healthcare settings.

Australia's high density of CT scanners makes the nation an attractive market for broad CT:VQ™ implementation.

The technology proves particularly valuable for facilities lacking onsite nuclear medicine services while simultaneously helping hospitals and imaging centres with existing nuclear medicine capabilities preserve that capacity for other diagnostic and therapeutic applications. This dual benefit positions CT:VQ™ as a resource-efficient solution for healthcare systems facing capacity constraints. The approval arrives as healthcare systems increasingly prioritize scalable and affordable technologies that leverage existing imaging resources. Rather than requiring substantial capital investment in new equipment or specialized infrastructure, CT:VQ™ enables functional lung assessment using resources already deployed across Australian healthcare facilities. This approach aligns with broader healthcare trends emphasizing cost-effectiveness and accessibility.

CT:VQ™ has already shown its clinical utility in various parts of the world. After being granted FDA clearance in 2025 for deployment in some of the most prestigious medical institutions in the US, such as Stanford, Cleveland Clinic, UCSD Health, University of Chicago Medicine, University of Miami, and SimonMed (one of the largest private outpatient radiology networks in the USA). The rapid increase in the use of the technology by some of the top healthcare providers in the USA demonstrates the clinical utility of the technology and its market demand among providers. The recent clearance in Australia allows 4DMedical to grow its presence in Australia while also supporting the continued global expansion of its business. This will also provide Australian healthcare providers with the opportunity to improve their diagnostic capabilities without having to invest significant capital or disrupt their existing workflows. As healthcare systems continue to look for innovative methods to maximize currently available resources and improve patient outcomes, CT:VQ™ represents a tremendous step forward in making respiratory imaging technology available at a reasonable cost.